{"protocolSection":{"identificationModule":{"nctId":"NCT03596177","orgStudyIdInfo":{"id":"D5670C00021"},"organization":{"fullName":"MedImmune LLC","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus","officialTitle":"An Exploratory Phase 2a, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"statusVerifiedDate":"2022-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-09-26","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-12-22","type":"ACTUAL"},"completionDateStruct":{"date":"2019-12-22","type":"ACTUAL"},"studyFirstSubmitDate":"2018-06-11","studyFirstSubmitQcDate":"2018-07-20","studyFirstPostDateStruct":{"date":"2018-07-23","type":"ACTUAL"},"resultsFirstSubmitDate":"2020-12-16","resultsFirstSubmitQcDate":"2020-12-16","resultsFirstPostDateStruct":{"date":"2021-01-15","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-12-21","lastUpdatePostDateStruct":{"date":"2023-01-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"MedImmune LLC","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"An exploratory study to evaluate the effect of MEDI0382 on energy balance in overweight and obese participants with type 2 diabetes mellitus","detailedDescription":"An exploratory Phase 2a, randomised, double-blind, placebo-controlled study to evaluate the effect of MEDI0382 on energy balance in overweight and obese participants with type 2 diabetes mellitus"},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II","Obesity"],"keywords":["Diabetes Mellitus, Type II","Obesity","MEDI0382"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Randomised, Double-Blind, Placebo-Controlled","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":28,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"MEDI0382","type":"EXPERIMENTAL","description":"Participants will receive subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.","interventionNames":["Drug: MEDI0382","Drug: Placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"MEDI0382","description":"MEDI0382 will be administered subcutaneously, titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.","armGroupLabels":["MEDI0382"]},{"type":"DRUG","name":"Placebo","description":"Placebo will be administered subcutaneously for 16 days in the single-blind treatment period in both MEDI0382 and placebo arms, and SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period in placebo arm.","armGroupLabels":["MEDI0382","Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percent Change in Body Weight From Baseline to Day 59","description":"Percent change in body weight from baseline to Day 59 is reported. Day 17 was considered as baseline for this outcome measure. The last observation carried forward (LOCF) analysis was used for missing data imputation for Day 59.","timeFrame":"Baseline (Day 17) and Day 59"}],"secondaryOutcomes":[{"measure":"Percent Change in Total Energy Intake From the ad Libitum Lunch From Baseline to Day 32 and Day 59","description":"Total energy intake in kilojoules (kJ) were recorded in a food diary after ad libitum lunch on Days 16, 32, and 59. The ad libitum lunch was a standardised solid meal with food of known macronutrient content. Participants were advised to eat freely until they feel comfortably full and the meal duration was flexible according to participant's preference. During the meal, the quantity of food ingested was recorded by study site staff without participants' awareness that food consumption was recorded. Percent change in total energy intake from the ad libitum lunch is reported. Day 16 was considered as baseline for this outcome measure. The LOCF analysis was used for missing data imputation for Day 59.","timeFrame":"Baseline (Day 16), Day 32, and Day 59"},{"measure":"Change in Total Energy Intake From the ad Libitum Lunch From Baseline to Day 32 and Day 59","description":"Total energy intake in kilojoules (kJ) were recorded in a food diary after ad libitum lunch on Days 16, 32, and 59. The ad libitum lunch was a standardised solid meal with food of known macronutrient content. Participants were advised to eat freely until they feel comfortably full and the meal duration was flexible according to participant's preference. During the meal, the quantity of food ingested was recorded by study site staff without participants' awareness that food consumption was recorded. Change in total energy intake from the ad libitum lunch is reported. Day 16 was considered as baseline for this outcome measure. The LOCF analysis was used for missing data imputation for Day 59.","timeFrame":"Baseline (Day 16) to Day 32 and Day 59"},{"measure":"Percent Change in Total Energy Expenditure (TEE) as Measured by Whole Room Indirect Calorimetry From Baseline to Day 58","description":"A whole room calorimetry assessment was used to measure gaseous exchange while exercising and therefore indirect estimates of energy expenditure over a 24-hour period. For assessment, participants had to enter the whole room calorimeter for up to 36 hours and reside inside for this entire duration (include toilet visits). During the time in the calorimeter participants were asked to exercise on an exercise bike for 15-minute intervals at 4 times. During these sessions participants were asked to aim for a heart rate of 65% of maximum (defined as 220 beats per minute minus age) and complete the full 15-minute session. In addition, participants abstained from caffeinated drinks for at least 24 hours prior to measurements as caffeine may increase energy expenditure (EE) and dietary advice was given to ensure participants had a neutral energy balance prior to whole calorimetry assessments. Percent change in TEE is reported. Day 15 was considered as baseline for this outcome measure.","timeFrame":"Baseline (Day 15) and Day 58"},{"measure":"Change in TEE as Measured by Whole Room Indirect Calorimetry From Baseline to Day 58","description":"A whole room calorimetry assessment was used to measure gaseous exchange while exercising and therefore indirect estimates of energy expenditure over a 24-hour period. For the assessment, participants had to enter the whole room calorimeter for up to 36 hours and reside inside for this entire duration (this will include toilet visits too). During the time in the calorimeter participants were asked to exercise on an exercise bike for 15-minute intervals at 4 times. During these sessions participants were asked to aim for a heart rate of 65% of maximum (defined as 220 beats per minute minus age) and complete the full 15-minute session. In addition, participants abstained from caffeinated drinks for at least 24 hours prior to measurements as caffeine may increase EE and dietary advice was given to ensure participants had a neutral energy balance prior to whole calorimetry assessments. Change in TEE is reported. Day 15 was considered as baseline for this outcome measure.","timeFrame":"Baseline (Day 15) and Day 58"},{"measure":"Percent Change in Activity Energy Expenditure (AEE) as Measured by Whole Room Indirect Calorimetry From Baseline to Day 58","description":"A whole room calorimetry assessment was used to measure gaseous exchange while exercising and therefore indirect estimates of energy expenditure over a 24-hour period. For the assessment, participants had to enter the whole room calorimeter for up to 36 hours and reside inside for this entire duration (this will include toilet visits too). During the time in the calorimeter participants were asked to exercise on an exercise bike for 15-minute intervals at 4 times. During these sessions participants were asked to aim for a heart rate of 65% of maximum (defined as 220 beats per minute minus age) and complete the full 15-minute session. In addition, participants abstained from caffeinated drinks for at least 24 hours prior to measurements as caffeine may increase EE and dietary advice was given to ensure participants had a neutral energy balance prior to whole calorimetry assessments. Percent change in AEE is reported. Day 15 was considered as baseline for this outcome measure.","timeFrame":"Baseline (Day 15) and Day 58"},{"measure":"Change in AEE as Measured by Whole Room Indirect Calorimetry From Baseline to Day 58","description":"A whole room calorimetry assessment was used to measure gaseous exchange while exercising and therefore indirect estimates of energy expenditure over a 24-hour period. For the assessment, participants had to enter the whole room calorimeter for up to 36 hours and reside inside for this entire duration (this will include toilet visits too). During the time in the calorimeter participants were asked to exercise on an exercise bike for 15-minute intervals at 4 times. During these sessions participants were asked to aim for a heart rate of 65% of maximum (defined as 220 beats per minute minus age) and complete the full 15-minute session. In addition, participants abstained from caffeinated drinks for at least 24 hours prior to measurements as caffeine may increase EE and dietary advice was given to ensure participants had a neutral energy balance prior to whole calorimetry assessments. Change in AEE is reported. Day 15 was considered as baseline for this outcome measure.","timeFrame":"Baseline (Day 15) and Day 58"},{"measure":"Percent Change in Resting Energy Expenditure (REE) as Measured by Whole Room Indirect Calorimetry From Baseline to Day 58","description":"The REE represents the amount of calories required for a 24-hour period by the body during a non-active period and is assessed by whole room indirect calorimetry method. Percent change in REE is reported. Day 15 was considered as baseline for this outcome measure.","timeFrame":"Baseline (Day 15) and Day 58"},{"measure":"Change in REE as Measured by Whole Room Indirect Calorimetry From Baseline to Day 58","description":"The REE represents the amount of calories required for a 24-hour period by the body during a non-active period and is assessed by whole room indirect calorimetry method. Change in REE is reported. Day 15 was considered as baseline for this outcome measure.","timeFrame":"Baseline (Day 15) and Day 58"},{"measure":"Percent Change in REE as Measured by Hood Indirect Calorimetry From Baseline to Day 32","description":"Hood calorimetry assessment was used to measure REE. A large plastic hood is placed over participants head for 20 minutes and measurements of gaseous exchange are undertaken. Participants were rested for at least 1 hour prior to hood calorimetry measures; during a hood calorimetry assessment the participants were asked to remain quiet and rested for 40 minutes in total with 10 minutes before and after the assessment to allow for room air assessment. Percent change in REE is reported. Day 16 was considered as baseline for this outcome measure.","timeFrame":"Baseline (Day 16) and Day 32"},{"measure":"Change in REE as Measured by Hood Indirect Calorimetry From Baseline to Day 32","description":"Hood calorimetry assessment was used to measure REE. A large plastic hood is placed over participants head for 20 minutes and measurements of gaseous exchange are undertaken. Participants were rested for at least 1 hour prior to hood calorimetry measures; during a hood calorimetry assessment the participants were asked to remain quiet and rested for 40 minutes in total with 10 minutes before and after the assessment to allow for room air assessment. Change in REE is reported. Day 16 was considered as baseline for this outcome measure.","timeFrame":"Baseline (Day 16) and Day 32"},{"measure":"Change in Body Weight From Baseline to Day 59","description":"Change in body weight from baseline to Day 59 is reported. Day 17 was considered as baseline for this outcome measure. The LOCF analysis was used for missing data imputation for Day 59.","timeFrame":"Baseline (Day 17) and Day 59"},{"measure":"Percent Change in Total Body Fat Mass as Measured by Dual-energy X-ray Absorptiometry (DXA) From Baseline to Day 59","description":"The total body fat mass was measured in kilograms (kg) using DXA. Participants body was scanned using DXA scanner and total body fat mass was determined. Percent change in total body fat mass is reported. Day -1 was considered as baseline for this outcome measure.","timeFrame":"Baseline (Day -1) and Day 59"},{"measure":"Change in Total Body Fat Mass as Measured by DXA From Baseline to Day 59","description":"The total body fat mass was measured in kg using DXA. Participants body was scanned using DXA scanner and total body fat mass was determined. Change in total body fat mass is reported. Day -1 was considered as baseline for this outcome measure.","timeFrame":"Baseline (Day -1) and Day 59"},{"measure":"Percent Change in Total Body Fat Mass: Lean Mass Ratio as Measured by DXA From Baseline to Day 59","description":"The total body fat mass and lean body mass was measured in kg using DXA. Participants body was scanned using DXA scanner and total body fat mass and lean mass was determined. Percent change in total body fat mass:lean mass (TBFM:LM) ratio is reported. Day -1 was considered as baseline for this outcome measure.","timeFrame":"Baseline (Day -1) and Day 59"},{"measure":"Change in Total Body Fat Mass: Lean Mass Ratio as Measured by DXA From Baseline to Day 59","description":"The total body fat mass and lean body mass was measured in kg using DXA. Participants body was scanned using DXA scanner and total body fat mass and lean mass was determined. Change in total body fat mass:lean mass (TBFM:LM) ratio is reported. Day -1 was considered as baseline for this outcome measure.","timeFrame":"Baseline (Day -1) and Day 59"},{"measure":"Change in Fasting Glucose During a Mixed-meal Tolerance Test (MMTT) From Baseline to Day 59","description":"The MMTT involves consumption of a standardized solid breakfast meal within 5 minutes, following a minimum 12 hours fast, and timed serial blood samples are obtained for measurement of glucose levels through 240 minutes with no additional food intake during this time. Change in fasting glucose is reported. Day -1 was considered as baseline for this outcome measure.","timeFrame":"Baseline (Day -1) and Day 59"},{"measure":"Percent Change in Glucose Area Under the Concentration-time Curve at 0 to 4 Hours (AUC0-4hrs) During a MMTT From Baseline to Day 59","description":"The MMTT involves consumption of a standardized solid breakfast meal within 5 minutes, following a minimum 12 hours fast, and timed serial blood samples are obtained for measurement of glucose levels through 240 minutes with no additional food intake during this time. Percent change in glucose AUC0-4hrs during MMTT is reported. Day -1 was considered as baseline for this outcome measure.","timeFrame":"Baseline (Day -1) and Day 59"},{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)","description":"An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life threatening experience immediate risk of dying, persistent or significant disability/incapacity, and congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. From Day 1 to Day 16 all participants in both treatment arms received placebo so that analysis of energy intake in participants who were randomised to MEDI0382 may be performed. Hence, TEAEs were not applicable for Day 1 to Day 16. The TEAEs were recorded and reported for double-blind treatment period ie, from Day 17.","timeFrame":"Day 17 through 28 days post last dose (approximately 14 months)"},{"measure":"Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs","description":"Number of participants with clinical laboratory abnormalities reported as TEAEs are reported. Clinical laboratory abnormalities are defined as any abnormal findings in analysis of serum chemistry, hematology, and urinalysis. From Day 1 to Day 16 all participants in both treatment arms received placebo so that analysis of energy intake in participants who were randomised to MEDI0382 may be performed. Hence, TEAEs were not applicable for Day 1 to Day 16. The TEAEs were recorded and reported for double-blind treatment period ie, from Day 17.","timeFrame":"Day 17 through 28 days post last dose (approximately 14 months)"},{"measure":"Number of Participants With Abnormal Vital Signs Reported as TEAEs","description":"Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs reported as TEAEs included any abnormal findings in body temperature, blood pressure, pulse rate, and respiratory rate. From Day 1 to Day 16 all participants in both treatment arms received placebo so that analysis of energy intake in participants who were randomised to MEDI0382 may be performed. Hence, TEAEs were not applicable for Day 1 to Day 16. The TEAEs were recorded and reported for double-blind treatment period ie, from Day 17.","timeFrame":"Day 17 through 28 days post last dose (approximately 14 months)"},{"measure":"Number of Participants With Abnormal Electrocardiograms (ECGs) Reported as TEAEs","description":"Number of participants with abnormal ECG reported as TEAEs are reported. From Day 1 to Day 16 all participants in both treatment arms received placebo so that analysis of energy intake in participants who were randomised to MEDI0382 may be performed. Hence, TEAEs were not applicable for Day 1 to Day 16. The TEAEs were recorded and reported for double-blind treatment period ie, from Day 17.","timeFrame":"Day 17 through 28 days post last dose (approximately 14 months)"},{"measure":"Number of Participants With Positive Anti-drug Antibodies (ADAs) to MEDI0382","description":"Number of participants with positive ADA to MEDI0382 are reported. Treatment-boosted ADA is defined as baseline ADA titer that was boosted to a 4-fold or higher level following drug administration. Treatment-emergent ADA is defined as the sum of treatment-induced ADA (post-baseline positive only) and treatment-boosted ADA. From Day 1 to Day 16 all participants in both treatment arms received placebo so that analysis of energy intake in participants who were randomised to MEDI0382 may be performed. Hence, ADA were not applicable for Day 1 to Day 16. The ADAs were recorded and reported for double-blind treatment period ie, from Day 17.","timeFrame":"Day 17 (predose), Day 32 (predose), Day 59; and 28 days post last dose (approximately 14 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Participants aged \\>= 30 and \\<= 75 years at screening\n2. Provision of signed and dated written informed consent (except for consent for genetic and non-genetic research and additional optional assessments) prior to any protocol-related procedures\n3. Body Mass Index \\> 28 and \\<= 40 kg/m\\^2 at screening\n4. Glycated haemoglobin (HbA1c) \\<= 8.0% at screening\n5. Diagnosed with type 2 diabetes (T2DM) with glucose control managed with metformin, with or without a dipeptidyl peptidase 4 (DPPIV) inhibitor, Sodium-glucose co-transporter-2 inhibitors (SGLT2i), sulfonylurea, or meglitinide, where no significant dose change (increase or decrease \\> 50%) has occurred in the 3 months prior to screening; if the participant is on dual therapy, a 4-week washout of the non-metformin therapy (DPPIV inhibitor, SGLT2i, sulfonylurea, or meglitinide) will be required prior to Visit 4.\n6. Female participants of childbearing potential must have a negative pregnancy test at screening and randomisation, and must not be lactating.\n7. Female participants of childbearing potential who are sexually active with a non-sterilised male partner must be using at least one highly effective method of contraception from screening and must agree to continue using such precautions up until 4 weeks after the last dose of study drug\n\nExclusion Criteria:\n\n1. History of, or any existing condition(s) that, in the opinion of the investigator, would interfere with evaluation of the study drug, put the participant at risk, influence the participant's ability to participate or affect the interpretation of the results of the study and/or any participant unable or unwilling to follow study procedures\n2. Any participant with a cardiac pacemaker or implanted/portable electronic device\n3. Any participant who has received another study drug as part of a clinical study or a Glucagon-like peptide-1 (GLP-1) analogue-containing preparation within the last 30 days or 5 half-lives of the drug (whichever is longer) at the time of screening (Visit 1)\n4. Any participant who has received any of the following medications within the specified timeframe prior to Visit 2: herbal preparations or drugs licensed for control of body weight or appetite (eg, orlistat, bupropion, naltrexone, phentermine-topiramate, phentermine, lorcaserin, opiates, domperidone, metoclopramide, or other drugs known to alter gastric emptying)\n5. Concurrent participation in another study with a study drug and prior randomisation in this study is prohibited\n6. Severe allergy/hypersensitivity to any of the proposed study treatments, excipients, or standardised meals\n7. Symptoms of acutely decompensated blood glucose control (eg, thirst, polyuria, weight loss), a history of type 1 diabetes mellitus or diabetic ketoacidosis, or if the participant has been treated with daily SC insulin within 90 days prior to screening.\n8. Abnormal thyroid stimulating hormone (TSH) level of \\< 0.03 Milli-International Units Per Litre (mIU/L) or \\> 10 mIU/L confirmed on two consecutive tests\n9. Regularly engage in high intensity exercise at least three times per week or have done so in the prior three months\n10. Clinically significant inflammatory bowel disease, gastroparesis or other severe disease or surgery affecting the upper gastrointestinal tract (including weight-reducing surgery and procedures) which may affect gastric emptying or could affect the interpretation of safety and tolerability data\n11. Acute or chronic pancreatitis\n12. Significant hepatic disease (except for nonalcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening:\n\n    1. Aspartate transaminase (AST) \\>= 3 × upper limit of normal (ULN)\n    2. Alanine transaminase (ALT) \\>= 3 × ULN\n    3. Total bilirubin \\>= 2 × ULN\n13. Impaired renal function defined as estimated glomerular filtration rate (eGFR) \\< 45 mL/minute/1.73 m\\^2 at screening (GFR estimated according to the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) or the Modification of Diet in Renal Disease (MDRD) using MDRD Study Equation isotope dilution mass spectrometry-traceable \\[International System of Units (SI) units\\]\n14. Poorly controlled hypertension defined as:\n\n    1. Systolic blood pressure (BP) \\> 180 mm Hg\n    2. Diastolic BP or \\> 100 mm Hg After 10 minutes of supine rest and confirmed by repeated measurement at screening.\n\n    Participants who fail BP screening criteria may be considered for 24-hour ambulatory BP monitoring at the discretion of the investigator. Participants who maintain a mean 24-hour BP \\<= 180/100 mmHg with a preserved nocturnal dip of \\> 15% will be considered eligible\n15. Unstable angina pectoris, myocardial infarction, transient ischemic attack or stroke within 3 months prior to screening, or participants who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 6 months or who are due to undergo these procedures at the time of screening\n16. Severe congestive heart failure (New York Heart Association Class III or IV)\n17. Basal calcitonin level \\> 50 ng/L at screening or history/family history of medullary thyroid carcinoma or multiple endocrine neoplasia\n18. History of neoplastic disease within 5 years prior to screening, except for adequately treated basal cell, squamous cell skin cancer, or in situ cervical cancer\n19. Any positive results for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV) antibody\n20. Substance dependence or history of alcohol abuse and/or excess alcohol intake\n21. Involvement of any AstraZeneca, Medimmune Ltd, contract research organization (CRO), or National Institute for Health Research/Wellcome Trust Cambridge Clinical Research Facility employee or their close relatives","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Research Site","city":"Cambridge","zip":"CB2 0QQ","country":"United Kingdom","geoPoint":{"lat":52.2,"lon":0.11667}}]},"referencesModule":{"references":[{"pmid":"38562018","type":"DERIVED","citation":"Golubic R, Kennet J, Parker V, Robertson D, Luo D, Hansen L, Jermutus L, Ambery P, Ryaboshapkina M, Surakala M, Laker RC, Venables M, Koulman A, Park A, Evans M. Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity. Diabetes Obes Metab. 2024 Jul;26(7):2634-2644. doi: 10.1111/dom.15579. Epub 2024 Apr 1."}],"seeAlsoLinks":[{"label":"D5670C00021 CSP redacted","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5670C00021&amp;attachmentIdentifier=bf8d7d39-e3d7-4035-a973-30f83c2db923&amp;fileName=D5670C00021-clinical-protocol-amendment-5-Redacted1.pdf&amp;versionIdentifier="},{"label":"D5670C00021 SAP redacted","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5670C00021&amp;attachmentIdentifier=0fba087b-4c08-4dd3-a44f-0946d4df5d91&amp;fileName=D5670C00021_Statistical_Analysis_Plan_Redacted_V2.0.pdf&amp;versionIdentifier="},{"label":"CSR Addendum synopsis\\_Redacted","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5670C00021&amp;attachmentIdentifier=e435c4b6-40df-49c5-9623-000e54c22d01&amp;fileName=D5670C00021_CSR_Addendum_synopsis_Redacted.pdf&amp;versionIdentifier="}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Due to COVID-19 pandemic a full analysis could not be performed due to logistical challenges and equipment failure and no further conclusions can be drawn. The results from the secondary analyses presented in this CSR Addendum do not impact any of the conclusions presented in the CSR, (Data cut off \\[DCO\\] 31 January 2020), see details in \"Limitations and Caveats\" section","groups":[{"id":"FG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"FG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"periods":[{"title":"Single Blind Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"19"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"18"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]},{"title":"Double Blind Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"18"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"6"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Death during safety follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"As-treated population included all participants who received any dose of study drug and analyzed according to the treatment they actually received.","groups":[{"id":"BG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"BG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"28"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62.2","spread":"7.2"},{"groupId":"BG001","value":"59.5","spread":"8.4"},{"groupId":"BG002","value":"60.4","spread":"8.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"25"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"27"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"26"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Body Weight From Baseline to Day 59","description":"Percent change in body weight from baseline to Day 59 is reported. Day 17 was considered as baseline for this outcome measure. The last observation carried forward (LOCF) analysis was used for missing data imputation for Day 59.","populationDescription":"Modified intent-to-treat (ITT) population: Participants in ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Day 59.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Percent change in body weight","timeFrame":"Baseline (Day 17) and Day 59","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"14"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.40","lowerLimit":"-2.66","upperLimit":"-0.13"},{"groupId":"OG001","value":"-3.98","lowerLimit":"-4.85","upperLimit":"-3.10"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.011","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-2.58","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.15","ciUpperLimit":"-1.00"}]},{"type":"SECONDARY","title":"Percent Change in Total Energy Intake From the ad Libitum Lunch From Baseline to Day 32 and Day 59","description":"Total energy intake in kilojoules (kJ) were recorded in a food diary after ad libitum lunch on Days 16, 32, and 59. The ad libitum lunch was a standardised solid meal with food of known macronutrient content. Participants were advised to eat freely until they feel comfortably full and the meal duration was flexible according to participant's preference. During the meal, the quantity of food ingested was recorded by study site staff without participants' awareness that food consumption was recorded. Percent change in total energy intake from the ad libitum lunch is reported. Day 16 was considered as baseline for this outcome measure. The LOCF analysis was used for missing data imputation for Day 59.","populationDescription":"mITT population: Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Days 32 and 59.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Percent change in total energy intake","timeFrame":"Baseline (Day 16), Day 32, and Day 59","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"14"}]}],"classes":[{"title":"Percent change at Day 32","categories":[{"measurements":[{"groupId":"OG000","value":"-5.170","lowerLimit":"-23.344","upperLimit":"13.003"},{"groupId":"OG001","value":"-50.652","lowerLimit":"-63.480","upperLimit":"-37.823"}]}]},{"title":"Percent change at Day 59","categories":[{"measurements":[{"groupId":"OG000","value":"-10.598","lowerLimit":"-31.316","upperLimit":"10.119"},{"groupId":"OG001","value":"-51.922","lowerLimit":"-66.546","upperLimit":"-37.297"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Statistical Analysis for Day 32","nonInferiorityType":"SUPERIORITY","pValue":"0.002","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-45.481","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-67.777","ciUpperLimit":"-23.186"},{"groupIds":["OG000","OG001"],"groupDescription":"Statistical Analysis for Day 59","nonInferiorityType":"SUPERIORITY","pValue":"0.011","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-41.323","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-66.740","ciUpperLimit":"-15.907"}]},{"type":"SECONDARY","title":"Change in Total Energy Intake From the ad Libitum Lunch From Baseline to Day 32 and Day 59","description":"Total energy intake in kilojoules (kJ) were recorded in a food diary after ad libitum lunch on Days 16, 32, and 59. The ad libitum lunch was a standardised solid meal with food of known macronutrient content. Participants were advised to eat freely until they feel comfortably full and the meal duration was flexible according to participant's preference. During the meal, the quantity of food ingested was recorded by study site staff without participants' awareness that food consumption was recorded. Change in total energy intake from the ad libitum lunch is reported. Day 16 was considered as baseline for this outcome measure. The LOCF analysis was used for missing data imputation for Day 59.","populationDescription":"mITT population: Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Days 32 and 59.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Kilojoules","timeFrame":"Baseline (Day 16) to Day 32 and Day 59","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"14"}]}],"classes":[{"title":"Change at Day 32","categories":[{"measurements":[{"groupId":"OG000","value":"-126.271","lowerLimit":"-647.387","upperLimit":"394.846"},{"groupId":"OG001","value":"-1677.465","lowerLimit":"-2045.322","upperLimit":"-1309.607"}]}]},{"title":"Change at Day 59","categories":[{"measurements":[{"groupId":"OG000","value":"-410.816","lowerLimit":"-1107.896","upperLimit":"286.263"},{"groupId":"OG001","value":"-1743.331","lowerLimit":"-2235.400","upperLimit":"-1251.261"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Statistical Analysis for Day 32","nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-1551.194","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2190.515","ciUpperLimit":"-911.873"},{"groupIds":["OG000","OG001"],"groupDescription":"Statistical Analysis for Day 59","nonInferiorityType":"SUPERIORITY","pValue":"0.015","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-1332.515","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2187.711","ciUpperLimit":"-477.318"}]},{"type":"SECONDARY","title":"Percent Change in Total Energy Expenditure (TEE) as Measured by Whole Room Indirect Calorimetry From Baseline to Day 58","description":"A whole room calorimetry assessment was used to measure gaseous exchange while exercising and therefore indirect estimates of energy expenditure over a 24-hour period. For assessment, participants had to enter the whole room calorimeter for up to 36 hours and reside inside for this entire duration (include toilet visits). During the time in the calorimeter participants were asked to exercise on an exercise bike for 15-minute intervals at 4 times. During these sessions participants were asked to aim for a heart rate of 65% of maximum (defined as 220 beats per minute minus age) and complete the full 15-minute session. In addition, participants abstained from caffeinated drinks for at least 24 hours prior to measurements as caffeine may increase energy expenditure (EE) and dietary advice was given to ensure participants had a neutral energy balance prior to whole calorimetry assessments. Percent change in TEE is reported. Day 15 was considered as baseline for this outcome measure.","populationDescription":"mITT population: Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Day 58.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Percent change in TEE","timeFrame":"Baseline (Day 15) and Day 58","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.032","lowerLimit":"-2.833","upperLimit":"6.898"},{"groupId":"OG001","value":"-1.141","lowerLimit":"-4.825","upperLimit":"2.544"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.384","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-3.173","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.368","ciUpperLimit":"3.022"}]},{"type":"SECONDARY","title":"Change in TEE as Measured by Whole Room Indirect Calorimetry From Baseline to Day 58","description":"A whole room calorimetry assessment was used to measure gaseous exchange while exercising and therefore indirect estimates of energy expenditure over a 24-hour period. For the assessment, participants had to enter the whole room calorimeter for up to 36 hours and reside inside for this entire duration (this will include toilet visits too). During the time in the calorimeter participants were asked to exercise on an exercise bike for 15-minute intervals at 4 times. During these sessions participants were asked to aim for a heart rate of 65% of maximum (defined as 220 beats per minute minus age) and complete the full 15-minute session. In addition, participants abstained from caffeinated drinks for at least 24 hours prior to measurements as caffeine may increase EE and dietary advice was given to ensure participants had a neutral energy balance prior to whole calorimetry assessments. Change in TEE is reported. Day 15 was considered as baseline for this outcome measure.","populationDescription":"mITT population: Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Day 58.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"kilojoules/kg fat body mass","timeFrame":"Baseline (Day 15) and Day 58","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.969","lowerLimit":"-8.364","upperLimit":"20.302"},{"groupId":"OG001","value":"-4.070","lowerLimit":"-14.924","upperLimit":"6.783"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.351","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-10.039","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-28.287","ciUpperLimit":"8.209"}]},{"type":"SECONDARY","title":"Percent Change in Activity Energy Expenditure (AEE) as Measured by Whole Room Indirect Calorimetry From Baseline to Day 58","description":"A whole room calorimetry assessment was used to measure gaseous exchange while exercising and therefore indirect estimates of energy expenditure over a 24-hour period. For the assessment, participants had to enter the whole room calorimeter for up to 36 hours and reside inside for this entire duration (this will include toilet visits too). During the time in the calorimeter participants were asked to exercise on an exercise bike for 15-minute intervals at 4 times. During these sessions participants were asked to aim for a heart rate of 65% of maximum (defined as 220 beats per minute minus age) and complete the full 15-minute session. In addition, participants abstained from caffeinated drinks for at least 24 hours prior to measurements as caffeine may increase EE and dietary advice was given to ensure participants had a neutral energy balance prior to whole calorimetry assessments. Percent change in AEE is reported. Day 15 was considered as baseline for this outcome measure.","populationDescription":"mITT population: Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Day 58.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Percent change in AEE","timeFrame":"Baseline (Day 15) and Day 58","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.446","lowerLimit":"-6.836","upperLimit":"5.943"},{"groupId":"OG001","value":"-0.261","lowerLimit":"-5.139","upperLimit":"4.618"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.968","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"0.186","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.858","ciUpperLimit":"8.229"}]},{"type":"SECONDARY","title":"Change in AEE as Measured by Whole Room Indirect Calorimetry From Baseline to Day 58","description":"A whole room calorimetry assessment was used to measure gaseous exchange while exercising and therefore indirect estimates of energy expenditure over a 24-hour period. For the assessment, participants had to enter the whole room calorimeter for up to 36 hours and reside inside for this entire duration (this will include toilet visits too). During the time in the calorimeter participants were asked to exercise on an exercise bike for 15-minute intervals at 4 times. During these sessions participants were asked to aim for a heart rate of 65% of maximum (defined as 220 beats per minute minus age) and complete the full 15-minute session. In addition, participants abstained from caffeinated drinks for at least 24 hours prior to measurements as caffeine may increase EE and dietary advice was given to ensure participants had a neutral energy balance prior to whole calorimetry assessments. Change in AEE is reported. Day 15 was considered as baseline for this outcome measure.","populationDescription":"mITT population: Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Day 58.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"kilojoules/kg fat body mass","timeFrame":"Baseline (Day 15) and Day 58","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.132","lowerLimit":"-3.259","upperLimit":"0.995"},{"groupId":"OG001","value":"-0.265","lowerLimit":"-1.889","upperLimit":"1.359"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.580","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"0.867","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.810","ciUpperLimit":"3.545"}]},{"type":"SECONDARY","title":"Percent Change in Resting Energy Expenditure (REE) as Measured by Whole Room Indirect Calorimetry From Baseline to Day 58","description":"The REE represents the amount of calories required for a 24-hour period by the body during a non-active period and is assessed by whole room indirect calorimetry method. Percent change in REE is reported. Day 15 was considered as baseline for this outcome measure.","populationDescription":"mITT population:Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Day 58.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Percent change in REE","timeFrame":"Baseline (Day 15) and Day 58","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.113","lowerLimit":"3.254","upperLimit":"12.972"},{"groupId":"OG001","value":"4.468","lowerLimit":"0.816","upperLimit":"8.120"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.324","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-3.645","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.894","ciUpperLimit":"2.603"}]},{"type":"SECONDARY","title":"Change in REE as Measured by Whole Room Indirect Calorimetry From Baseline to Day 58","description":"The REE represents the amount of calories required for a 24-hour period by the body during a non-active period and is assessed by whole room indirect calorimetry method. Change in REE is reported. Day 15 was considered as baseline for this outcome measure.","populationDescription":"mITT population: Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Day 58.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"kilojoules/kg fat body mass","timeFrame":"Baseline (Day 15) and Day 58","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.237","lowerLimit":"4.104","upperLimit":"22.369"},{"groupId":"OG001","value":"7.565","lowerLimit":"0.701","upperLimit":"14.429"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.412","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-5.672","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-17.415","ciUpperLimit":"6.072"}]},{"type":"SECONDARY","title":"Percent Change in REE as Measured by Hood Indirect Calorimetry From Baseline to Day 32","description":"Hood calorimetry assessment was used to measure REE. A large plastic hood is placed over participants head for 20 minutes and measurements of gaseous exchange are undertaken. Participants were rested for at least 1 hour prior to hood calorimetry measures; during a hood calorimetry assessment the participants were asked to remain quiet and rested for 40 minutes in total with 10 minutes before and after the assessment to allow for room air assessment. Percent change in REE is reported. Day 16 was considered as baseline for this outcome measure.","populationDescription":"mITT population: Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Day 32.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Percent Change in REE","timeFrame":"Baseline (Day 16) and Day 32","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.189","lowerLimit":"-5.955","upperLimit":"8.332"},{"groupId":"OG001","value":"8.546","lowerLimit":"3.138","upperLimit":"13.954"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.177","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"7.357","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.742","ciUpperLimit":"16.456"}]},{"type":"SECONDARY","title":"Change in REE as Measured by Hood Indirect Calorimetry From Baseline to Day 32","description":"Hood calorimetry assessment was used to measure REE. A large plastic hood is placed over participants head for 20 minutes and measurements of gaseous exchange are undertaken. Participants were rested for at least 1 hour prior to hood calorimetry measures; during a hood calorimetry assessment the participants were asked to remain quiet and rested for 40 minutes in total with 10 minutes before and after the assessment to allow for room air assessment. Change in REE is reported. Day 16 was considered as baseline for this outcome measure.","populationDescription":"mITT population: Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Day 32.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"kilojoules/kg fat body mass","timeFrame":"Baseline (Day 16) and Day 32","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.316","lowerLimit":"-11.080","upperLimit":"17.712"},{"groupId":"OG001","value":"18.502","lowerLimit":"7.604","upperLimit":"29.400"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.168","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"15.186","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.151","ciUpperLimit":"33.523"}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline to Day 59","description":"Change in body weight from baseline to Day 59 is reported. Day 17 was considered as baseline for this outcome measure. The LOCF analysis was used for missing data imputation for Day 59.","populationDescription":"mITT population: Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Day 59.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"kg","timeFrame":"Baseline (Day 17) and Day 59","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"14"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.26","lowerLimit":"-2.48","upperLimit":"-0.05"},{"groupId":"OG001","value":"-3.80","lowerLimit":"-4.65","upperLimit":"-2.96"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.009","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-2.54","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.05","ciUpperLimit":"-1.03"}]},{"type":"SECONDARY","title":"Percent Change in Total Body Fat Mass as Measured by Dual-energy X-ray Absorptiometry (DXA) From Baseline to Day 59","description":"The total body fat mass was measured in kilograms (kg) using DXA. Participants body was scanned using DXA scanner and total body fat mass was determined. Percent change in total body fat mass is reported. Day -1 was considered as baseline for this outcome measure.","populationDescription":"mITT population: Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Day 59.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Percent change in total body fat mass","timeFrame":"Baseline (Day -1) and Day 59","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.218","lowerLimit":"-8.249","upperLimit":"-0.186"},{"groupId":"OG001","value":"-9.340","lowerLimit":"-12.343","upperLimit":"-6.337"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.107","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-5.122","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.364","ciUpperLimit":"0.119"}]},{"type":"SECONDARY","title":"Change in Total Body Fat Mass as Measured by DXA From Baseline to Day 59","description":"The total body fat mass was measured in kg using DXA. Participants body was scanned using DXA scanner and total body fat mass was determined. Change in total body fat mass is reported. Day -1 was considered as baseline for this outcome measure.","populationDescription":"mITT population: Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Day 59.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Kg","timeFrame":"Baseline (Day -1) and Day 59","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.455","lowerLimit":"-2.806","upperLimit":"-0.103"},{"groupId":"OG001","value":"-3.303","lowerLimit":"-4.310","upperLimit":"-2.296"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.085","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-1.848","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.605","ciUpperLimit":"-0.091"}]},{"type":"SECONDARY","title":"Percent Change in Total Body Fat Mass: Lean Mass Ratio as Measured by DXA From Baseline to Day 59","description":"The total body fat mass and lean body mass was measured in kg using DXA. Participants body was scanned using DXA scanner and total body fat mass and lean mass was determined. Percent change in total body fat mass:lean mass (TBFM:LM) ratio is reported. Day -1 was considered as baseline for this outcome measure.","populationDescription":"mITT population: Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Day 59.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Percent change in TBFM:LM ratio","timeFrame":"Baseline (Day -1) and Day 59","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.667","lowerLimit":"-4.934","upperLimit":"1.600"},{"groupId":"OG001","value":"-4.827","lowerLimit":"-7.298","upperLimit":"-2.355"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.204","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-3.159","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.326","ciUpperLimit":"1.007"}]},{"type":"SECONDARY","title":"Change in Total Body Fat Mass: Lean Mass Ratio as Measured by DXA From Baseline to Day 59","description":"The total body fat mass and lean body mass was measured in kg using DXA. Participants body was scanned using DXA scanner and total body fat mass and lean mass was determined. Change in total body fat mass:lean mass (TBFM:LM) ratio is reported. Day -1 was considered as baseline for this outcome measure.","populationDescription":"mITT population: Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Day 59.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Baseline (Day -1) and Day 59","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.010","lowerLimit":"-0.027","upperLimit":"0.007"},{"groupId":"OG001","value":"-0.029","lowerLimit":"-0.042","upperLimit":"-0.016"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.145","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-0.019","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.041","ciUpperLimit":"0.003"}]},{"type":"SECONDARY","title":"Change in Fasting Glucose During a Mixed-meal Tolerance Test (MMTT) From Baseline to Day 59","description":"The MMTT involves consumption of a standardized solid breakfast meal within 5 minutes, following a minimum 12 hours fast, and timed serial blood samples are obtained for measurement of glucose levels through 240 minutes with no additional food intake during this time. Change in fasting glucose is reported. Day -1 was considered as baseline for this outcome measure.","populationDescription":"mITT population: Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Day 59.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"mg/dL","timeFrame":"Baseline (Day -1) and Day 59","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.600","lowerLimit":"-21.673","upperLimit":"-3.527"},{"groupId":"OG001","value":"-38.601","lowerLimit":"-45.360","upperLimit":"-31.842"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-26.001","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-37.801","ciUpperLimit":"-14.201"}]},{"type":"SECONDARY","title":"Percent Change in Glucose Area Under the Concentration-time Curve at 0 to 4 Hours (AUC0-4hrs) During a MMTT From Baseline to Day 59","description":"The MMTT involves consumption of a standardized solid breakfast meal within 5 minutes, following a minimum 12 hours fast, and timed serial blood samples are obtained for measurement of glucose levels through 240 minutes with no additional food intake during this time. Percent change in glucose AUC0-4hrs during MMTT is reported. Day -1 was considered as baseline for this outcome measure.","populationDescription":"mITT population: Participants in the ITT population (who received any study drug) who received at least one dose of the study drug in the double-blind treatment period, and analyzed according to their randomized treatment group. Here, \"number of participants analyzed\" denotes those participants who were evaluable at baseline and Day 59.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Percentage change in glucose AUC0-4hrs","timeFrame":"Baseline (Day -1) and Day 59","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.773","lowerLimit":"-12.528","upperLimit":"-1.018"},{"groupId":"OG001","value":"-19.105","lowerLimit":"-23.434","upperLimit":"-14.777"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.010","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Net)","paramValue":"-12.332","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-19.726","ciUpperLimit":"-4.938"}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)","description":"An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life threatening experience immediate risk of dying, persistent or significant disability/incapacity, and congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. From Day 1 to Day 16 all participants in both treatment arms received placebo so that analysis of energy intake in participants who were randomised to MEDI0382 may be performed. Hence, TEAEs were not applicable for Day 1 to Day 16. The TEAEs were recorded and reported for double-blind treatment period ie, from Day 17.","populationDescription":"Participants who received any study drug in the double-blind treatment period and were analyzed according to the treatment they received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 17 through 28 days post last dose (approximately 14 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"18"}]}],"classes":[{"title":"Any TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"17"}]}]},{"title":"Any TESAEs","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs","description":"Number of participants with clinical laboratory abnormalities reported as TEAEs are reported. Clinical laboratory abnormalities are defined as any abnormal findings in analysis of serum chemistry, hematology, and urinalysis. From Day 1 to Day 16 all participants in both treatment arms received placebo so that analysis of energy intake in participants who were randomised to MEDI0382 may be performed. Hence, TEAEs were not applicable for Day 1 to Day 16. The TEAEs were recorded and reported for double-blind treatment period ie, from Day 17.","populationDescription":"Participants who received any study drug in the double-blind treatment period and were analyzed according to the treatment they received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 17 through 28 days post last dose (approximately 14 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Abnormal Vital Signs Reported as TEAEs","description":"Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs reported as TEAEs included any abnormal findings in body temperature, blood pressure, pulse rate, and respiratory rate. From Day 1 to Day 16 all participants in both treatment arms received placebo so that analysis of energy intake in participants who were randomised to MEDI0382 may be performed. Hence, TEAEs were not applicable for Day 1 to Day 16. The TEAEs were recorded and reported for double-blind treatment period ie, from Day 17.","populationDescription":"Participants who received any study drug in the double-blind treatment period and were analyzed according to the treatment they received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 17 through 28 days post last dose (approximately 14 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Abnormal Electrocardiograms (ECGs) Reported as TEAEs","description":"Number of participants with abnormal ECG reported as TEAEs are reported. From Day 1 to Day 16 all participants in both treatment arms received placebo so that analysis of energy intake in participants who were randomised to MEDI0382 may be performed. Hence, TEAEs were not applicable for Day 1 to Day 16. The TEAEs were recorded and reported for double-blind treatment period ie, from Day 17.","populationDescription":"Participants who received any study drug in the double-blind treatment period and were analyzed according to the treatment they received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 17 through 28 days post last dose (approximately 14 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Positive Anti-drug Antibodies (ADAs) to MEDI0382","description":"Number of participants with positive ADA to MEDI0382 are reported. Treatment-boosted ADA is defined as baseline ADA titer that was boosted to a 4-fold or higher level following drug administration. Treatment-emergent ADA is defined as the sum of treatment-induced ADA (post-baseline positive only) and treatment-boosted ADA. From Day 1 to Day 16 all participants in both treatment arms received placebo so that analysis of energy intake in participants who were randomised to MEDI0382 may be performed. Hence, ADA were not applicable for Day 1 to Day 16. The ADAs were recorded and reported for double-blind treatment period ie, from Day 17.","populationDescription":"Participants who received any study drug in the double-blind treatment period and were analyzed according to the treatment they received. Here, \"number of participants analyzed\" denotes those participants who had post-baseline ADA results.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 17 (predose), Day 32 (predose), Day 59; and 28 days post last dose (approximately 14 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period."},{"id":"OG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"14"}]}],"classes":[{"title":"ADA positive post-BL","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"Treatment-boosted ADA","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Treatment-emergent ADA","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Day 17 through 28 days post last dose (approximately 14 months)","description":"From Day 1 to Day 16 all participants in both treatment arms received placebo so that analysis of energy intake in participants who were randomised to MEDI0382 may be performed. Hence, TEAEs were not applicable for Day 1 to Day 16. The TEAEs were recorded and reported for double-blind treatment period ie, from Day 17.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Participants received subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period.","deathsNumAffected":0,"deathsNumAtRisk":7,"seriousNumAffected":0,"seriousNumAtRisk":7,"otherNumAffected":5,"otherNumAtRisk":7},{"id":"EG001","title":"MEDI0382","description":"Participants received SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.","deathsNumAffected":1,"deathsNumAtRisk":18,"seriousNumAffected":2,"seriousNumAtRisk":18,"otherNumAffected":16,"otherNumAtRisk":18}],"seriousEvents":[{"term":"Coronary artery thrombosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Haematoma muscle","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]}],"otherEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":18}]},{"term":"Breath odour","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":18}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":7},{"groupId":"EG001","numEvents":6,"numAffected":3,"numAtRisk":18}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":18}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":18}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":18}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":7},{"groupId":"EG001","numEvents":19,"numAffected":13,"numAtRisk":18}]},{"term":"Retching","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":18}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":18}]},{"term":"Injection site haemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":18}]},{"term":"Eye contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Skin abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":18}]},{"term":"Electrocardiogram t wave amplitude decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":18}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":18}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Rotator cuff syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":18}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":2,"numAtRisk":7},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":18}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":18}]},{"term":"Restless legs syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Coital bleeding","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Blister","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"For Participant Flow section, Pre-assignment details:\n\nData not collected for Secondary Outcome Measures #24 and #25:\n\n* Percentage change in TEE as measured by doubly labelled water from baseline (Day 17) to End of Treatment (EOT; Day 58 or 59\\],\n* Change in TEE as measured by doubly labelled water from baseline (Day 17) to End of Treatment (EOT; Day 58 or 59\\])."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome."},"pointOfContact":{"title":"Victoria Parker","organization":"MedImmune, LLC","email":"information.center@astrazeneca.com","phone":"+44 747 1357172"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-03-20","uploadDate":"2022-12-21T04:31","filename":"Prot_002.pdf","size":3129559},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-02-23","uploadDate":"2022-12-21T04:31","filename":"SAP_003.pdf","size":3271007}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"},{"id":"D009765","term":"Obesity"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D050177","term":"Overweight"},{"id":"D044343","term":"Overnutrition"},{"id":"D009748","term":"Nutrition Disorders"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"C000624433","term":"cotadutide"}]}},"hasResults":true}